131 related articles for article (PubMed ID: 16277859)
1. [Retrospective observation of curative effects on MDS refractory anemia with combination of all-trans retinoic acid, 1, 25-dihydroxyvitamin D3 and androgen].
Zhou FL; Zhang WG; Cao XM; Chen YX; He AL; Liu J; Zhao WH; Ma XR; Chen G
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):861-6. PubMed ID: 16277859
[TBL] [Abstract][Full Text] [Related]
2. [Long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome: follow-up of 60 cases].
Guan M; Chen SC; Ge CW
Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):919-22. PubMed ID: 19671296
[TBL] [Abstract][Full Text] [Related]
3. [Low dose all-trans retinoic acid and androgen therapy for patients with myelodysplastic syndrome].
Guan M; Chen SC; Li RS; Ge CW; Zhu HL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Dec; 12(6):774-8. PubMed ID: 15631659
[TBL] [Abstract][Full Text] [Related]
4. [Cyclosporine A based therapy for myelodysplastic syndrome].
Li ZL; Gong M; Xu SH; Huang FZ; Chen YR; Ma YG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):867-70. PubMed ID: 16277860
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of primary refractory anemia with a combination regimen of all-trans retinoic acid, calcitriol, and androgen.
Zhang W; Zhou F; Cao X; Cheng Y; He A; Liu J; Ma X; Chen G
Leuk Res; 2006 Aug; 30(8):935-42. PubMed ID: 16445979
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide for the treatment of patients with myelodysplastic syndromes.
Strupp C; Germing U; Aivado M; Misgeld E; Haas R; Gattermann N
Leukemia; 2002 Jan; 16(1):1-6. PubMed ID: 11840256
[TBL] [Abstract][Full Text] [Related]
7. All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study.
Aul C; Runde V; Gattermann N
Blood; 1993 Nov; 82(10):2967-74. PubMed ID: 8219188
[TBL] [Abstract][Full Text] [Related]
8. Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor.
Hofmann WK; Ganser A; Seipelt G; Ottmann OG; Zander C; Geissler G; Hoffmann K; Höffken K; Fischer JT; Isele G; Hoelzer D
Ann Hematol; 1999 Mar; 78(3):125-30. PubMed ID: 10211754
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of myelodysplastic syndrome patients with moderate/severe anaemia receiving human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3: independent positive impact of erythroid response on survival.
Crisà E; Foli C; Passera R; Darbesio A; Garvey KB; Boccadoro M; Ferrero D
Br J Haematol; 2012 Jul; 158(1):99-107. PubMed ID: 22571649
[TBL] [Abstract][Full Text] [Related]
10. Therapy of 'high risk' myelodysplastic syndromes with an association of low-dose Ara-C, retinoic acid and 1,25-dihydroxyvitamin D3.
De Rosa L; Montuoro A; De Laurenzi A
Biomed Pharmacother; 1992; 46(5-7):211-7. PubMed ID: 1467449
[TBL] [Abstract][Full Text] [Related]
11. All-trans retinoic acid in the treatment of myelodysplastic syndromes.
Visani G; Tosi P; Manfroi S; Ottaviani E; Finelli C; Cenacchi A; Bendandi M; Tura S
Leuk Lymphoma; 1995 Oct; 19(3-4):277-80. PubMed ID: 8535219
[TBL] [Abstract][Full Text] [Related]
12. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N
Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213
[TBL] [Abstract][Full Text] [Related]
13. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
[TBL] [Abstract][Full Text] [Related]
15. Effect of combination therapy with all-trans-retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes.
Ganser A; Seipelt G; Verbeek W; Ottmann OG; Maurer A; Kolbe K; Hess U; Elsner S; Reutzel R; Wörmann B
Leukemia; 1994 Mar; 8(3):369-75. PubMed ID: 7510354
[TBL] [Abstract][Full Text] [Related]
16. Treatment of myelodysplastic syndromes with all-trans retinoic acid. Leukemia Study Group of the Ministry of Health and Welfare.
Ohno R; Naoe T; Hirano M; Kobayashi M; Hirai H; Tubaki K; Oh H
Blood; 1993 Mar; 81(5):1152-4. PubMed ID: 8443376
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes.
Ferrero D; Darbesio A; Giai V; Genuardi M; Dellacasa CM; Sorasio R; Bertini M; Boccadoro M
Br J Haematol; 2009 Feb; 144(3):342-9. PubMed ID: 19036104
[TBL] [Abstract][Full Text] [Related]
18. Immunologic characteristics and prognosis of myelodysplastic syndrome new subtype: refractory anemia with excess blasts-II.
Wei J; Zhou XF; Zhao F; Zhou JF; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):111-6. PubMed ID: 19236759
[TBL] [Abstract][Full Text] [Related]
19. [A preliminary report on treatment of myelodysplastic syndrome with cyclosporin a and androgen].
Wang JW; Ning F; Liu XD; Lou JX; Chen P; Liu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Dec; 12(6):855-7. PubMed ID: 15631678
[TBL] [Abstract][Full Text] [Related]
20. [Curative effects of cyclosporin A therapy upon myelodysplastic syndrome].
Chen SC; Jiang B; Da WM; Gong M; Guan M
Zhonghua Yi Xue Za Zhi; 2006 Oct; 86(38):2711-5. PubMed ID: 17199984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
